James A. Robinson Jr.
Known title: DirectorCIK: 0001734295
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
ELDN Presents Phase 2 Data, Gets FDA Fast Track for Tegoprubart. Eledon presented updated long‑term results from its Phase 2 BESTOW extension study at the International Congress of The Transplantation Society. The data support the continued development of tegoprubart for kidney transplant patients. The FDA also granted Fast Track designation for tegoprubart, and the company plans to start a Phase 3 LEGACY study in the fourth quarter of 2026. These milestones highlight progress in the company’s clinical program.
Transaction History
| URGN | ▲ Buy | Option Exercise | 2,000 | — | 8/26/2026 | View on chart |
| URGN | ▲ Buy | Option Exercise | 2,000 | — | 5/26/2026 | View on chart |
| ELDN | ▲ Buy | Option Exercise | 3,430 | $0 | 1/10/2026 | View on chart |
| URGN | ▲ Buy | Option Exercise | 2,000 | — | 11/26/2025 | View on chart |
| URGN | ▲ Buy | Option Exercise | 2,000 | — | 2/26/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
UroGen Pharma highlighted as emerging GARP stock
UroGen Pharma is being discussed as an emerging GARP stock, indicating growing interest from analysts. The average target price of $60.00, with a range of $48.00 to $75.00, suggests potential upside from its current level. The stock trades near its 12‑touch support at $40.15 and has a moderate RSI of 35.3, indicating it is not overbought. These factors may influence how investors view its future performance.
UroGen Pharma highlighted as emerging GARP stock. UroGen Pharma is being discussed as an emerging GARP stock, indicating growing interest from analysts. The average target price of $60.00, with a range of $48.00 to $75.00, suggests potential upside from its current level. The stock trades near its 12‑touch support at $40.15 and has a moderate RSI of 35.3, indicating it is not overbought. These factors may influence how investors view its future performance.